ustransplant.org

Transplant Statistics: Annual Report : Reference Tables

Annual Report | Chapters | Data By Category | Data By Organ | Technical Notes | Glossary | Appendices

Table 14.10
De Novo Posttransplant Solid Malignancy, 1992 to 2001
Heart Recipients

Malignancies by Type Year of Transplant
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Total # of Post-Tx Malignancies 266 230 243 265 218 168 141 88 38 8
Squamous/Basal Cell Carcinoma 179 141 167 156 147 116 84 55 15 6
Melanoma 3 6 3 9 6 8 5 6 - -
Kaposi Sarcoma - 1 1 - 3 - 2 - - -
Central Nervous System - - 2 3 - 1 1 - 2 -
Genito-Urinary (1) 9 13 10 14 8 4 7 7 2 -
Gastro-Intestinal (2) 26 26 23 29 22 16 18 4 9 2
Primary Hepatic Tumor 1 2 1 1 1 1 1 1 - -
Metastatic Hepatic Tumor 3 4 5 1 4 1 - 1 - -
Larynx/Bronchi/Lung 23 16 13 23 14 11 9 8 3 -
Breast/Thyroid/Adrenal 4 4 1 7 4 5 6 3 - -
Leukemia 3 2 2 - - - 1 - - -
Sarcoma (3) 4 1 2 5 2 - - - 1 -
Other 11 14 12 15 7 5 6 1 6 -
Unknown - - 1 2 - - 1 2 - -
Squamous/Basal Cell Carcinoma 67.3% 61.3% 68.7% 58.9% 67.4% 69.0% 59.6% 62.5% 39.5% 75.0%
Melanoma 1.1% 2.6% 1.2% 3.4% 2.8% 4.8% 3.5% 6.8% - -
Kaposi Sarcoma - 0.4% 0.4% - 1.4% - 1.4% - - -
Central Nervous System - - 0.8% 1.1% - 0.6% 0.7% - 5.3% -
Genito-Urinary (1) 3.4% 5.7% 4.1% 5.3% 3.7% 2.4% 5.0% 8.0% 5.3% -
Gastro-Intestinal (2) 9.8% 11.3% 9.5% 10.9% 10.1% 9.5% 12.8% 4.5% 23.7% 25.0%
Primary Hepatic Tumor 0.4% 0.9% 0.4% 0.4% 0.5% 0.6% 0.7% 1.1% - -
Metastatic Hepatic Tumor 1.1% 1.7% 2.1% 0.4% 1.8% 0.6% - 1.1% - -
Larynx/Bronchi/Lung 8.6% 7.0% 5.3% 8.7% 6.4% 6.5% 6.4% 9.1% 7.9% -
Breast/Thyroid/Adrenal 1.5% 1.7% 0.4% 2.6% 1.8% 3.0% 4.3% 3.4% - -
Leukemia 1.1% 0.9% 0.8% - - - 0.7% - - -
Sarcoma (3) 1.5% 0.4% 0.8% 1.9% 0.9% - - - 2.6% -
Other 4.1% 6.1% 4.9% 5.7% 3.2% 3.0% 4.3% 1.1% 15.8% -
Unknown - - 0.4% 0.8% - - 0.7% 2.3% - -
Total # of Patients 181 177 192 186 165 133 109 74 35 7

Source: OPTN/SRTR Data as of August 1, 2002.
(-) = None in category.
(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.
(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary
tract, pancreas.
(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.
Patients may have more than one posttransplant malignancy reported due to multiple follow-up forms.
Recipient malignancy statistics are based on voluntary reporting to the OPTN.

Annual Report | Chapters | Data By Category | Data By Organ | Technical Notes | Glossary | Appendices

Center-Specific Reports | OPO Reports | National Reports | Data Accuracy | Report Timeline

Home | Who We Are | What We Do | About Transplants | Transplant Statistics | Research Resources | Contact Us | Site Map

SRTR Site designed and maintained by Diamond Bullet Design & URREA.